Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib as second-line monotherapy in RAS-mutant advanced colorectal cancer
2015-001105-13Phase 2Completed
- Sponsor
- Istituto Nazionale Tumori IRCCS Fondazione Pascale
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of regorafenib in colorectal cancer (CRC) and rectal adenocarcinoma, sponsored by Istituto Nazionale Tumori IRCCS Fondazione Pascale. Primary endpoint: 6-month progression-free rate. Started Sep 2021; status: completed.
02
Drugs
regorafenib
03
Conditions
colorectal cancer (CRC)rectal adenocarcinoma
Beyond the preview
Go deeper on 2015-001105-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001105-13.